A pilot double‐blind safety and feasibility randomized controlled trial of high‐dose intravenous zinc in hospitalized COVID‐19 patients
| Autor: | Ary Serpa Neto, Christine F McDonald, John El-Khoury, Damien M Bolton, Daryl A Jones, Joseph Ischia, Rinaldo Bellomo, Jason A Trubiano, Marlon Perera, Oneel Patel, Vidyasagar Chinni, Emily J See |
|---|---|
| Přispěvatelé: | Intensive Care Medicine |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Short Communication Short Communications Pilot Projects medicine.disease_cause Placebo Infusion Site law.invention 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Double-Blind Method Randomized controlled trial COVID‐19 law Virology medicine Humans 030212 general & internal medicine Adverse effect Aged Aged 80 and over Inpatients Dose-Response Relationship Drug SARS-CoV-2 business.industry zinc COVID-19 trial protocol Middle Aged medicine.disease Respiration Artificial COVID-19 Drug Treatment Oxygen Increased serum zinc Infectious Diseases Anesthesia Injections Intravenous randomized controlled trial Zinc deficiency Feasibility Studies Female 030211 gastroenterology & hepatology Irritation business |
| Zdroj: | Journal of Medical Virology Journal of medical virology, 93(5), 3261-3267. Wiley-Liss Inc. |
| ISSN: | 1096-9071 0146-6615 |
| Popis: | Zinc inhibits replication of the SARS‐CoV virus. We aimed to evaluate the safety, feasibility, and biological effect of administering high‐dose intravenous zinc (HDIVZn) to patients with COVID‐19. We performed a Phase IIa double‐blind, randomized controlled trial to compare HDIVZn to placebo in hospitalized patients with COVID‐19. We administered trial treatment per day for a maximum of 7 days until either death or hospital discharge. We measured zinc concentration at baseline and during treatment and observed patients for any significant side effects. For eligible patients, we randomized and administered treatment to 33 adult participants to either HDIVZn (n = 15) or placebo (n = 18). We observed no serious adverse events throughout the study for a total of 94 HDIVZn administrations. However, three participants in the HDIVZn group reported infusion site irritation. Mean serum zinc on Day 1 in the placebo, and the HDIVZn group was 6.9 ± 1.1 and 7.7 ± 1.6 µmol/l, respectively, consistent with zinc deficiency. HDIVZn, but not placebo, increased serum zinc levels above the deficiency cutoff of 10.7 µmol/l (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text